Login to Your Account



Post-Acquisition Genzyme Bails On PTC Deal for DMD Candidate

By Jennifer Boggs


Tuesday, September 6, 2011
PTC Therapeutics Inc.'s Duchenne's muscular dystrophy (DMD) program looks to be the first casualty of Genzyme's Corp.'s acquisition by Sanofi SA, with the Cambridge, Mass.-based biotech handing back ex-North American rights to ataluren.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription